Partners Investment

Partners Investment is a venture capital firm established in 2000 and located in Seoul, South Korea. The firm specializes in investing in sectors such as internet, mobile, bio and healthcare, and information and communication technology. With a focus on responsible and long-term partnerships, Partners Investment aims to provide constructive contributions to its portfolio companies, supporting their growth and development in a dynamic market environment.

Jaewan Kim

Founder and CEO

Yong Ha Kim

Managing Director

111 past transactions

Dime Bio

Series A in 2025
Dime Bio is a drug development company for novel dementia treatments.

Arbor Biotechnologies

Series C in 2025
Arbor Biotechnologies, Inc., founded in 2016 and headquartered in Cambridge, Massachusetts, operates as a bio-discovery company in the biotechnology sector. The company focuses on developing genomic tools that enhance human health and sustainability. Utilizing a combination of artificial intelligence, genome sequencing, gene synthesis, and high-throughput screening, Arbor's platform accelerates the discovery of proteins and facilitates human diagnostic development. The technology aggregates genomic sequence data through AI and machine learning, enabling drug developers to replace entire genes and precisely correct mutations. This approach aims to streamline the development of curative treatments for previously incurable genetic diseases, ultimately improving the lives of patients affected by such conditions.

MediThinQ

Series B in 2025
MediThinQ is a medical technology company that specializes in the development and manufacture of advanced surgical glasses. These innovative glasses provide a unique surgical viewing experience, allowing surgeons to maintain a clear line of sight during complex procedures. Designed with comfort and ergonomics in mind, the glasses are lightweight and facilitate an enhanced auditory experience, thereby supporting surgeons in their tasks. MediThinQ's focus on improving surgical visibility and comfort reflects its commitment to advancing medical technology for better surgical outcomes.

JLT

Series B in 2025
JLT supplies industrial automation equipment solutions and focuses on technology improvement through an integrated welding solution development project.

Sizzle

Venture Round in 2025
Sizzle is a company that provides an integrated process analysis solution based on accumulated experience.

Aigen Sciences

Series A in 2024
AIGEN Sciences is an AI-driven drug discovery platform that focuses on providing research and development services for pharmaceutical innovations. The company specializes in discovering high-potency drugs that target specific cellular activities while minimizing off-target effects and toxicity. This approach allows AIGEN Sciences to facilitate the rapid development of effective medications at a lower cost, ultimately benefiting clients in the pharmaceutical industry.

StoreLink

Series C in 2024
StoreLink is an open market optimization platform that focuses on enhancing the performance of sellers in online shopping environments. The company utilizes artificial intelligence to analyze and process accurate online sales data, providing tools that maximize visibility for sellers. Additionally, StoreLink offers sales forecasting models that help clients improve their sales and revenue, making it easier for businesses to navigate the complexities of online retail.

Xpanner

Series B in 2024
Xpanner is a developer of a cloud-based construction management platform that aims to enhance productivity, management efficiency, and safety within the construction industry. By integrating various construction technology products, Xpanner provides a unified solution that allows construction teams to access and manage data from multiple sources through a single point of entry. This approach fosters collaboration among stakeholders, leading to improved project outcomes and an average productivity improvement of 15%. The platform also emphasizes environmental, social, and governance (ESG) enhancements, making it a comprehensive tool for modern construction management.

Dewcell Biotherapeutics

Series B in 2024
Dewcell Biotherapeutics specializes in the development of synthetic platelets using advanced biomimetic technology. The company focuses on human-derived stem cell-induced differentiation to convert stem cells into megakaryocytes, which are responsible for producing platelets. By harnessing this technology, Dewcell aims to mass-produce artificial platelets, addressing the critical shortage of blood-derived platelets. This innovative approach has the potential to enhance the availability of platelets for medical applications, thereby improving patient care and outcomes.

Dalpha

Series A in 2024
Dalpha specializes in creating customized artificial intelligence solutions for businesses. By leveraging its advanced AI technology, Dalpha helps enterprises enhance their revenue and reduce costs by addressing unique challenges. The company prioritizes data security and ownership, employing a secure cloud environment and differential privacy technology to protect sensitive information. This approach allows clients to access fast and accurate insights while maintaining the integrity of their data.

Artblood

Series A in 2024
Artblood is a cell-based artificial blood production company.

Surginex

Venture Round in 2024
Surginex is a biological drug development company focused on creating next-generation bio platforms and innovative pharmaceuticals. The company provides a range of services that include molecular biology, genetics, and both physical and chemical analyses. Additionally, Surginex employs advanced technologies, including artificial intelligence, to enhance drug discovery processes. Their comprehensive approach encompasses everything from molecular biology experiments and animal studies to the execution of clinical trials, all aimed at accelerating patient recovery and improving healthcare outcomes.

Soft Berry

Series A in 2024
Soft Berry is an electric vehicle charging platform.

DYNE Medical Group

Series B in 2024
DYNE Medical Group is a medical equipment manufacturer specializing in endoscopy devices and artificial intelligence solutions for urological surgery. The company focuses on developing advanced manufacturing technologies that enhance the capabilities of reusable flexible endoscopes. By employing unique optimization design and ultra-precision processing techniques, DYNE Medical Group aims to improve the effectiveness of endoscopic procedures, facilitating minimally invasive treatment options for patients. Additionally, the company is involved in creating AI-based diagnostic tools for cancer detection, positioning itself at the forefront of technological innovation in the medical field.

Cytonus Therapeutics

Series A in 2023
Cytonus Therapeutics, Inc. is a biotechnology company founded in 2018 and based in Columbus, Ohio. The company focuses on developing immune-oncology and gene therapies aimed at treating devastating and rare diseases. Cytonus combines artificial intelligence-driven drug discovery with a unique delivery system known as Cargocyte, which utilizes synthetic biology for precision treatment. The company's mission centers on addressing immune-related disorders through innovative approaches that enable targeted delivery and in vivo production of first-in-class therapeutics.

Quad Miners

Series B in 2023
Quad Miners is a cybersecurity software developer focused on addressing security threats and enhancing internet security. The company's software employs a machine learning-based artificial intelligence analysis engine, which allows for the storage of network traffic without data loss while effectively detecting threats and anomalies. This innovative approach enables customers to safeguard their data against malware attacks, providing reliable and accurate cyber defense solutions.

Harbinger Health

Series B in 2023
Harbinger Health is a biotechnology company focused on the early detection of cancer through a two-tier blood testing model. By integrating artificial intelligence and machine learning, the company aims to identify cancer at its earliest stages, even before symptoms become apparent. This innovative approach seeks to provide low-cost, multi-cancer blood tests that enhance diagnostic capabilities for healthcare professionals, ultimately facilitating more timely and effective interventions for patients.

BONABANK

Venture Round in 2023
BONABANK is an ERP software development company.

EndoRobotics

Series B in 2023
EndoRobotics is a healthcare company focused on advancing endoscopic surgery through the development of specialized robotic technology. The company is working on an endoscopic surgical assist robot along with a range of associated surgical instruments. These innovations aim to enhance the capabilities of endoscopic procedures, offering improved treatment options within the healthcare industry. By integrating robotics into endoscopy, EndoRobotics seeks to provide more effective and precise therapeutic interventions.

IMBiologics

Series B in 2023
IMBiologics is a biotechnology company focused on developing immunomodulatory antibody drugs aimed at achieving physiological balance. The company specializes in creating novel treatment options for autoimmune diseases and cancer through its innovative antibody-based biologics. By utilizing unique mechanisms of action to modulate the immune system, IMBiologics enables advancements in cancer treatment and enhances the potential for new therapeutic strategies in the field of modern biomedicine.

AltPep

Series B in 2023
AltPep Corp is a biomedical startup that specializes in diagnosing and treating amyloid diseases, which are known for their challenging nature. The company operates a proprietary peptide-based platform designed to identify and neutralize toxic precursors associated with these diseases. This innovative approach includes diagnostic and therapeutic applications, particularly focused on the early detection of toxic oligomers in Alzheimer's disease through a soluble oligomer binding assay. By enabling healthcare institutions to detect and address amyloid diseases at an earlier stage, AltPep aims to enhance human health outcomes and improve treatment options for patients suffering from these conditions.

K-NETZ

Series A in 2023
K-NETZ is an IT company that provides value-oriented R&D and possesses global technological competitiveness services.

Adcentrx Therapeutics

Series A in 2023
Adcentrx Therapeutics is a biotechnology company dedicated to advancing the development of protein conjugate therapeutics aimed at treating cancer and other serious diseases. The company focuses on creating targeted therapies that leverage the precise targeting capabilities of biologics combined with the therapeutic effectiveness of small molecule payloads. Through its innovative approach, Adcentrx seeks to enhance patient treatment options, offering next-generation therapies that aim to improve outcomes for individuals facing life-threatening conditions.

Ring Therapeutics

Series C in 2023
Ring Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing gene therapies through its innovative Anellovector platform. This platform leverages the biology of the human commensal virome to create redosable and targetable DNA therapies that address several limitations of existing gene therapies, such as restricted access to various tissues, risks associated with genomic integration, and issues with tolerability. Founded in 2017, the company aims to expand the applications of gene therapy beyond traditional gene replacement, targeting a wide range of conditions including genetic disorders, ophthalmology, oncology, and metabolic diseases. By doing so, Ring Therapeutics seeks to provide healthcare solutions that allow for a broader array of therapeutic modalities and improved patient outcomes.

Cytonus Therapeutics

Venture Round in 2023
Cytonus Therapeutics, Inc. is a biotechnology company founded in 2018 and based in Columbus, Ohio. The company focuses on developing immune-oncology and gene therapies aimed at treating devastating and rare diseases. Cytonus combines artificial intelligence-driven drug discovery with a unique delivery system known as Cargocyte, which utilizes synthetic biology for precision treatment. The company's mission centers on addressing immune-related disorders through innovative approaches that enable targeted delivery and in vivo production of first-in-class therapeutics.

Upstairs

Series A in 2022
Upstairs is an online platform or B2B marketplace for customers to buy or sell previously used and owned mobile phones.

LBox

Series B in 2022
LBox is a developer of a legal technology platform designed to simplify the online search for legal information. The company's digital platform functions as a search engine, allowing legal professionals to easily access case law, legal documents, and scholarly articles. This tool enhances the research process by enabling users to study various legal surveys and publications relevant to their cases, ultimately streamlining the acquisition of crucial legal information.

Sonde

Series B in 2022
Sonde Health is a digital medicine company focused on developing voice-based technologies for monitoring and diagnosing mental and respiratory health. The company's innovative platform utilizes mobile devices to capture and analyze subtle changes in voice, allowing for the creation of various health measurements related to brain, muscle, and respiratory function. By enabling users to track changes in their health over time, Sonde Health aims to identify early signs of disease, ultimately transforming the approach to health monitoring and diagnosis.

Mustbio

Series B in 2022
MustBio is a biotechnology company based in Seoul, South Korea, founded in 2021. The company focuses on developing therapeutics for cancer treatment, specifically in the field of immuno-oncology. Utilizing a multi-antibody technology, MustBio creates drugs that mimic a natural asymmetric IgG form, which allows for a high rate of double antibody formation. This innovative approach not only enhances the effectiveness of the treatments but also offers economic feasibility, making it possible for healthcare companies to provide effective therapies for a range of cancer types.

Aigen Sciences

Seed Round in 2022
AIGEN Sciences is an AI-driven drug discovery platform that focuses on providing research and development services for pharmaceutical innovations. The company specializes in discovering high-potency drugs that target specific cellular activities while minimizing off-target effects and toxicity. This approach allows AIGEN Sciences to facilitate the rapid development of effective medications at a lower cost, ultimately benefiting clients in the pharmaceutical industry.

Sentbe

Series C in 2022
Founded in 2015, SentBe is a global foreign exchange solutions provider specializing in remittance and payment services for both individuals and businesses. The company aims to create a world without financial borders by offering innovative cross-border payment solutions that enhance the competitiveness of its clients. SentBe operates an online remittance platform that enables efficient money transfers worldwide, focusing on international non-cent transfers by leveraging price differences between Bitcoin exchanges across countries. With extensive global partnerships and strong foreign exchange management capabilities, SentBe delivers a robust infrastructure that adheres to global standards, facilitating seamless financial transactions for its users.

Sharetreats

Series B in 2022
Sharetreats Innovation is a company based in Makati, Philippines, that has developed a platform enabling consumers to send and receive vouchers redeemable at select branches. After a payment is completed, treat codes are delivered via SMS, facilitating a straightforward gifting process. Additionally, Sharetreats promotes a cultural movement encouraging social interaction through casual gifts, offering a variety of stickers and greetings suitable for various occasions. This combination of digital vouchers and personalized greetings enhances the gifting experience for users.

Senda Biosciences

Series C in 2022
Senda Biosciences, founded in 2017 in Cambridge, Massachusetts, focuses on developing therapeutic applications for innovative treatments of human diseases. The company investigates the molecular relationships among bacterial, botanical, and human cells, aiming to understand how these interactions influence health and disease. By leveraging insights from these interspecies connections, Senda Biosciences seeks to create new categories of medicines and delivery methods that can assist medical professionals in providing effective treatments.

Cytonus Therapeutics

Seed Round in 2022
Cytonus Therapeutics, Inc. is a biotechnology company founded in 2018 and based in Columbus, Ohio. The company focuses on developing immune-oncology and gene therapies aimed at treating devastating and rare diseases. Cytonus combines artificial intelligence-driven drug discovery with a unique delivery system known as Cargocyte, which utilizes synthetic biology for precision treatment. The company's mission centers on addressing immune-related disorders through innovative approaches that enable targeted delivery and in vivo production of first-in-class therapeutics.

Quad Miners

Series A in 2022
Quad Miners is a cybersecurity software developer focused on addressing security threats and enhancing internet security. The company's software employs a machine learning-based artificial intelligence analysis engine, which allows for the storage of network traffic without data loss while effectively detecting threats and anomalies. This innovative approach enables customers to safeguard their data against malware attacks, providing reliable and accurate cyber defense solutions.

CONTEC

Series C in 2022
CONTEC is providing ground station services, satellite image processing, and application services. The company's ground station network supports VHF, UHF, S-Band, and X-Band frequencies for TT&C via high-performance receivers for high data rate reception. They especially focus on applications for urban change detection of smart cities and aim to provide the best service possible for local governments and therefore contribute to urban development. Contec's main goal of building a global ground station network and operating its own Earth observation satellites.

Rznomics

Series C in 2022
Rznomics is a biotechnology company founded by professor Lee Sung-wook's lab, focusing on the development of innovative gene therapy products aimed at treating liver cancer and other serious medical conditions. The company specializes in ribonucleic acid-based therapies that address significant unmet medical needs, particularly in the areas of cancer, degenerative neurological disorders, and hereditary diseases. By creating new biopharmaceuticals, Rznomics aims to provide medical practitioners with effective treatment options for challenging health issues, including various types of cancer and Alzheimer’s disease. The company has garnered recognition for its technological excellence, having been selected for the TIPS program, which highlights its commitment to advancing medical science.

Fastview

Series A in 2022
FastView is a company that specializes in content commerce and online marketing services, focusing on enhancing the production and distribution capabilities of soft content. It offers a range of services designed to support creators in developing and expanding their content businesses, including content marketing and online auto agency services. By providing these tailored marketing solutions, FastView aims to improve the overall effectiveness of content creators in reaching their target audiences and achieving their business goals.

Witchcraft

Seed Round in 2022
Witchcraft operates as a marketplace for crafting ideas into digital assets. It offers a secure platform for storing these digital assets indefinitely. The company's services extend to the realms of online auctions, online portals, and virtual reality. Witchcraft also provides a user-friendly and transparent blockchain wallet, known as Witch Wallet. This wallet ensures the ownership of digital assets through its 'Craft'ing feature.

StoreLink

Series B in 2022
StoreLink is an open market optimization platform that focuses on enhancing the performance of sellers in online shopping environments. The company utilizes artificial intelligence to analyze and process accurate online sales data, providing tools that maximize visibility for sellers. Additionally, StoreLink offers sales forecasting models that help clients improve their sales and revenue, making it easier for businesses to navigate the complexities of online retail.

Vastera

Series B in 2022
Bastera is a biotech company with the primary goal of developing groundbreaking treatments for cardiovascular and cancer diseases. Their approach involves targeting new redox signaling pathways, aiming to pioneer "first-in-class" therapies in these fields. Vastera was established in 2018 when SangWon Kang, a professor at Ewha Womans University, transferred a patent based on research results on redox signaling in blood vessels and cancer.

Astrogen

Series B in 2022
Astrogen is a biotechnology company focused on developing innovative drugs to address challenging neurological diseases. The company engages in clinical research to create treatment alternatives for conditions such as autism spectrum disorder and Alzheimer's disease. Through its drug development efforts, Astrogen aims to provide medical professionals with effective options to assist patients suffering from irreversible neurological disorders.

AmazeVR

Venture Round in 2022
AmazeVR is a virtual concert platform that facilitates immersive music experiences through advanced VR content creation and distribution technologies. Founded in 2015 by former executives of Kakao, the company offers an end-to-end solution that includes ultra-high-resolution custom cameras, cloud-based creation tools, and social interaction features allowing users to engage with friends as avatars. AmazeVR's platform enables fans to attend virtual concerts with their favorite artists, providing a novel way to experience live music. The company also employs both online and offline distribution methods, including the Amaze Tour, ensuring compliance with safety measures while reaching a broad audience.

Lysentech

Series A in 2021
LyseNTech is a biotechnology company focused on combating antibiotic-resistant bacteria through the development of innovative treatments. The company specializes in creating antibiotics derived from bacteriophages, which are viruses that specifically target and eliminate bacteria. Additionally, LyseNTech is engaged in the development of phage-derived endolysins and oncolytic bacteriophages, which are designed to deliver targeted anticancer therapies. This approach allows for the precise targeting and destruction of cancer cells, offering potential advancements in cancer treatment. By harnessing the unique properties of bacteriophages, LyseNTech aims to address critical challenges in both antibiotic resistance and cancer therapy.

Allo

Seed Round in 2021
Allo is a developer of a visual workspace platform aimed at improving collaboration among internal teams and external partners. The platform is designed to adapt to various workflows, facilitating activities such as brainstorming, project management, and team alignment. By leveraging technology, Allo offers a unique collaboration experience that includes web-based invitations and the integration of features from other applications. This approach enables organizations to enhance communication and cooperation among their teams, ultimately leading to more effective collaboration.

OGQ

Series B in 2021
OGQ is a developer of a social creator platform that facilitates connections between creators and their fans, allowing creators to sell their works directly. The platform hosts a diverse array of content, including images, videos, music, stickers, illustrations, and graphics in various formats, such as PSD and AI. With over 14 million creators, including photographers, musicians, and illustrators, OGQ serves a global audience, with significant user bases in the United States, India, and Russia. The platform has achieved substantial popularity, boasting 240 million app downloads and 2.6 billion content downloads, while maintaining a high user rating of 4.6 on Google Play. OGQ supports content in 30 languages, providing users with high-definition materials for various applications, including messaging services and search platforms.

OKXE

Series A in 2021
Okxe is an online marketplace designed to facilitate the buying and selling of motorcycles. The platform connects motorcycle sellers and buyers, utilizing artificial intelligence and big data to enhance the shopping experience. It features a diverse selection of verified motorcycles from various brands and stores, ensuring a safe and efficient environment for customers. By providing an open market, Okxe aims to streamline the e-commerce process for motorcycle enthusiasts, allowing them to explore different options and make informed purchasing decisions.

Cerecin

Series A in 2021
Cerecin is a healthcare company based in Denver, Colorado, that focuses on developing innovative therapeutics and products aimed at addressing neurological conditions, including memory impairment and Alzheimer's disease. Founded in 2001, the company utilizes lipid science to explore the therapeutic benefits of medium-chain triglycerides, which are intended to induce ketosis and enhance mitochondrial metabolism. Cerecin's offerings include pharmaceuticals, medical foods, diagnostics, medical devices, and e-health products. These evidence-based solutions are designed to provide clinicians with effective tools to support brain health and treat a variety of neurodegenerative diseases, ultimately striving to improve the lives of millions affected by these conditions.

IMBiologics

Series A in 2021
IMBiologics is a biotechnology company focused on developing immunomodulatory antibody drugs aimed at achieving physiological balance. The company specializes in creating novel treatment options for autoimmune diseases and cancer through its innovative antibody-based biologics. By utilizing unique mechanisms of action to modulate the immune system, IMBiologics enables advancements in cancer treatment and enhances the potential for new therapeutic strategies in the field of modern biomedicine.

Upstairs

Series A in 2021
Upstairs is an online platform or B2B marketplace for customers to buy or sell previously used and owned mobile phones.

Ring Therapeutics

Series B in 2021
Ring Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing gene therapies through its innovative Anellovector platform. This platform leverages the biology of the human commensal virome to create redosable and targetable DNA therapies that address several limitations of existing gene therapies, such as restricted access to various tissues, risks associated with genomic integration, and issues with tolerability. Founded in 2017, the company aims to expand the applications of gene therapy beyond traditional gene replacement, targeting a wide range of conditions including genetic disorders, ophthalmology, oncology, and metabolic diseases. By doing so, Ring Therapeutics seeks to provide healthcare solutions that allow for a broader array of therapeutic modalities and improved patient outcomes.

Drimaes

Series A in 2021
Drimaes is a developer of an automotive software platform focused on enhancing in-vehicle infotainment services. The company's innovative solutions aim to improve the comfort and enjoyment of mobility for users. By utilizing automated grade Linux and advanced technology, Drimaes optimizes hardware porting and adapts to micro-controller characteristics. Their platform facilitates better integration of smartphone applications into the driving interface, enhancing data interfacing and overall user experience.

Senda Biosciences

Series B in 2021
Senda Biosciences, founded in 2017 in Cambridge, Massachusetts, focuses on developing therapeutic applications for innovative treatments of human diseases. The company investigates the molecular relationships among bacterial, botanical, and human cells, aiming to understand how these interactions influence health and disease. By leveraging insights from these interspecies connections, Senda Biosciences seeks to create new categories of medicines and delivery methods that can assist medical professionals in providing effective treatments.

Newracle Genetics

Series B in 2021
Newracle Genetics is a bio venture company that develops gene therapy products for neurological diseases.

Medipixel

Series A in 2021
Medipixel, Inc., founded in 2017 and based in Seoul, South Korea, specializes in developing artificial intelligence-based diagnostic software and semi-autonomous surgical tools for lung cancer and cardiac disease interventions. The company employs a team of experts in computer vision, deep learning, and reinforcement learning, collaborating with leading healthcare institutions to enhance diagnostic and surgical processes. Medipixel offers several innovative solutions, including an AI-based diagnosis tool that assists doctors in identifying lesions during coronary angiography, a guide and planning solution that visualizes hidden coronary artery segments to facilitate guidewire manipulation, and an automated navigation engine that optimizes robotic control for surgical procedures. By integrating advanced AI technologies, Medipixel aims to improve the quality of medical care and patient outcomes in the field of surgery.

Cenyx Biotech

Series A in 2021
Cenyx Biotech is focused on advancing healthcare through its innovative platform that utilizes diagnostic and therapeutic nano-compounds based on nanozymes and nanoparticles. The company is developing a unique nano-biotech agent designed to simultaneously eliminate superoxide, hydrogen peroxide, and hydroxyl radicals. This approach aims to help patients and healthcare practitioners manage excessive inflammatory reactions, particularly in the early stages of subarachnoid hemorrhage. By addressing these critical factors, Cenyx Biotech seeks to transform treatment options and improve patient outcomes in the healthcare sector.

Anipen

Convertible Note in 2021
Anipen is a South Korean company focused on developing a 3D content platform that leverages augmented reality and deep learning technologies. The company specializes in creating applications for short video platforms and video games, enabling businesses to produce augmented reality web TV shows, social media promotional videos, and animated clips accessible on mobile devices. Anipen's innovative solutions facilitate the development of video communication and entertainment platforms, allowing enterprises to effectively promote their products and engage with their audiences.

Rznomics

Series B in 2021
Rznomics is a biotechnology company founded by professor Lee Sung-wook's lab, focusing on the development of innovative gene therapy products aimed at treating liver cancer and other serious medical conditions. The company specializes in ribonucleic acid-based therapies that address significant unmet medical needs, particularly in the areas of cancer, degenerative neurological disorders, and hereditary diseases. By creating new biopharmaceuticals, Rznomics aims to provide medical practitioners with effective treatment options for challenging health issues, including various types of cancer and Alzheimer’s disease. The company has garnered recognition for its technological excellence, having been selected for the TIPS program, which highlights its commitment to advancing medical science.

AmazeVR

Series B in 2021
AmazeVR is a virtual concert platform that facilitates immersive music experiences through advanced VR content creation and distribution technologies. Founded in 2015 by former executives of Kakao, the company offers an end-to-end solution that includes ultra-high-resolution custom cameras, cloud-based creation tools, and social interaction features allowing users to engage with friends as avatars. AmazeVR's platform enables fans to attend virtual concerts with their favorite artists, providing a novel way to experience live music. The company also employs both online and offline distribution methods, including the Amaze Tour, ensuring compliance with safety measures while reaching a broad audience.

AffaMed Therapeutics

Series B in 2021
AffaMed Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative pharmaceutical products. The company focuses on accelerating the clinical development of new therapies aimed at addressing significant unmet medical needs, particularly in the fields of ophthalmology, neurology, and psychiatry. By targeting these critical areas, AffaMed strives to create impactful solutions that improve the lives of patients globally.

Astrogen

Series B in 2020
Astrogen is a biotechnology company focused on developing innovative drugs to address challenging neurological diseases. The company engages in clinical research to create treatment alternatives for conditions such as autism spectrum disorder and Alzheimer's disease. Through its drug development efforts, Astrogen aims to provide medical professionals with effective options to assist patients suffering from irreversible neurological disorders.

EJN

Series A in 2020
EJN Corp. is an IT company based in Seoul, South Korea, that specializes in providing online community platforms and services tailored for gamers and streamers. Founded in 2016, the company operates several key platforms, including Battle.dog, which analyzes viewing data from e-sports competitions, and Twip, an online sales channel designed for creators and streamers. Additionally, EJN manages Twitch, a social community focused on gaming. The company also offers community and payment services to enhance game video streaming experiences.

Chatie

Venture Round in 2020
Chatie is a chat service software that specializes in a story-writing application aimed at enabling users to create and share narratives in a message format. The application supports various genres, including romantic, horror, and fanfiction, and allows for storytelling through text, video, photos, and sound, as well as offering optional endings. This versatility helps writers engage their audience effectively by presenting stories in a familiar and accessible format.

Checkmate Theraputics

Series A in 2020
Checkmate Therapeutics is a biotech company that discovers and develops novel approaches for cancer immunotherapy such as immuno-oncology.

Linewalks

Series A in 2020
Linewalks is a data technology company focused on the healthcare sector. It specializes in developing advanced data analysis tools that leverage big data to extract valuable insights. The company's artificial intelligence software analyzes real-world data generated from actual treatment environments, particularly in the context of treating cardiovascular disease. By monitoring treatment pathways and assessing individual risk factors, Linewalks empowers pharmaceutical companies and healthcare institutions to uncover crucial insights that enhance decision-making and improve patient outcomes.

Evidnet

Series A in 2020
EvidNet is a healthcare IT company focused on providing Real World Evidence (RWE) solutions derived from hospital data, aimed at enhancing research and business decision-making within the life sciences and healthcare sectors. Collaborating with over 50 university and general hospitals in Korea, EvidNet builds Real World Data (RWD) following the OMOP-CDM standard. Their FeederNet® data platform supports multi-institutional research and AI federated machine learning while ensuring privacy and security. The company specializes in managing clinical practice data through an interoperable, real-time integrated healthcare data network, offering tailored statistical analysis that meets the specific needs of hospitals and clients. By leveraging these advanced technologies, EvidNet delivers valuable insights that span from research and development to commercialization, ultimately contributing to the advancement of precision and predictive medicine.

Bagelcode

Series D in 2020
Bagelcode, Inc. is a mobile gaming company based in Seoul, South Korea, founded in 2012. It specializes in developing mobile social casino games, allowing users to engage in popular casino experiences such as slots and poker on web and mobile platforms. The company has a diverse workforce of over 170 members from various countries, including the United States, Canada, and Israel, fostering a global talent pool to enhance its gaming offerings. With a user base exceeding 45 million worldwide, Bagelcode has experienced significant growth, reportedly expanding at an average rate of over 250% in recent years. The company is committed to continuous innovation and seeks to position itself as a leader in the global gaming industry by attracting top talent and enhancing user experiences.

Astrogen

Series A in 2020
Astrogen is a biotechnology company focused on developing innovative drugs to address challenging neurological diseases. The company engages in clinical research to create treatment alternatives for conditions such as autism spectrum disorder and Alzheimer's disease. Through its drug development efforts, Astrogen aims to provide medical professionals with effective options to assist patients suffering from irreversible neurological disorders.

Hidden Sequence

Series B in 2020
Hidden Sequence is a production company that specializes in creating and financing drama, film, and television projects. The company focuses on producing films, telefilms, and stage dramas that feature original stories and local artists. By prioritizing freshly written narratives, Hidden Sequence aims to provide diverse content across various genres, catering to both artists and audiences.

OKXE

Series A in 2020
Okxe is an online marketplace designed to facilitate the buying and selling of motorcycles. The platform connects motorcycle sellers and buyers, utilizing artificial intelligence and big data to enhance the shopping experience. It features a diverse selection of verified motorcycles from various brands and stores, ensuring a safe and efficient environment for customers. By providing an open market, Okxe aims to streamline the e-commerce process for motorcycle enthusiasts, allowing them to explore different options and make informed purchasing decisions.

Radish

Series A in 2020
Radish is a mobile fiction platform that specializes in serialized storytelling, offering readers a diverse array of stories presented in bite-sized installments tailored for smartphone use. The platform allows readers to explore thousands of serials across multiple genres, including romance, fantasy, young adult, paranormal, mystery, and science fiction. Radish fosters direct interaction between readers and authors through live community chat rooms, enhancing the reader experience. For writers, Radish provides a unique opportunity to publish original works, revive previously published titles, and generate anticipation for upcoming stories, all while ensuring they receive immediate compensation and retain copyright ownership. This innovative approach is transforming the landscape of story consumption and production.

Z-emotion

Series A in 2020
Z-emotion is a technology company specializing in 3D garment simulation, aimed at facilitating the digital transformation of the fashion industry. Headquartered in South Korea, with additional offices in Hong Kong and the USA, the company offers a primary product called z-weave, a 3D CAD software that allows apparel professionals to visualize their fashion concepts. Z-emotion's platform is equipped with features such as predictive analytics, a virtual showroom, custom animation, and auto stitching, which enable users to make informed decisions in garment design. The company has garnered investment support from notable strategic partners, including LG Electronics, NAVER, HTC, and Shima Seiki, further solidifying its presence in the market.

Genecast

Series B in 2020
GeneCast specializes in cancer screening, monitoring, and precision care through innovative diagnostic technology. The company's method focuses on amplifying only mutated genes while preserving normal genes, enabling the detection and diagnosis of early-stage cancer. Utilizing a liquid biopsy approach, GeneCast analyzes mutant tumor DNA found in the blood, facilitating timely and accurate treatment options for cancer patients. This technology aims to enhance the precision of cancer care and improve patient outcomes.

Ubix Therapeutics

Series B in 2020
Ubix Therapeutics, Inc. is a research and development company based in Seoul, South Korea, focused on creating anti-cancer drugs through its innovative proteolysis targeting chimera platform technology. This approach employs inhibitor technology to degrade specific target proteins within cells, aiming to enhance therapeutic efficacy for various cancers. By binding to proteins associated with targeted diseases, Ubix Therapeutics seeks to provide effective and life-saving treatments for patients, thereby supporting medical professionals in their efforts to combat cancer.

Positive Hotel

Series A in 2020
Positive Hotel focuses on promoting sustainable wellness through a range of products that support a healthy lifestyle. The company offers Mediterranean diet products, including blends, olive capsules, and collagens, along with food ingredients, wellness boosters, and cosmetics. By providing these convenient and health-oriented products, Positive Hotel aims to help customers make nutritious choices and enhance their overall well-being.

Phantom AI

Series A in 2020
Phantom AI, Inc. specializes in developing advanced driver-assistance systems (ADAS) and artificial intelligence solutions for autonomous vehicles. Based in Burlingame, California, the company offers a suite of products, including PhantomVision, a deep learning-based computer vision solution that complies with Euro NCAP standards, enabling the detection of vehicles, pedestrians, cyclists, and traffic signals. Additionally, Phantom AI provides PhantomFusion, which integrates data from various sensors such as cameras, radar, and LiDAR to create a comprehensive environmental model. Their PhantomDrive solution focuses on ensuring safe vehicle movement by predicting the behavior of detected objects. By delivering a modular, software-based platform, Phantom AI allows original equipment manufacturers (OEMs) and Tier 1 suppliers to customize their integration of these technologies, aiming to reduce accidents, enhance driving experiences, and advance the development of self-driving technology.

AmazeVR

Series A in 2020
AmazeVR is a virtual concert platform that facilitates immersive music experiences through advanced VR content creation and distribution technologies. Founded in 2015 by former executives of Kakao, the company offers an end-to-end solution that includes ultra-high-resolution custom cameras, cloud-based creation tools, and social interaction features allowing users to engage with friends as avatars. AmazeVR's platform enables fans to attend virtual concerts with their favorite artists, providing a novel way to experience live music. The company also employs both online and offline distribution methods, including the Amaze Tour, ensuring compliance with safety measures while reaching a broad audience.

Olive Healthcare

Series B in 2019
Olive Healthcare is a digital healthcare company specializing in medical diagnostic devices with a focus on abdominal fat scanning and breast cancer diagnosis. Utilizing non-radiative and non-invasive near infrared (NIR) technology, along with artificial intelligence algorithms and big data processing, Olive Healthcare offers customized medical services. Their devices are designed to measure abdominal fat status and provide tailored exercise and diet guidance, helping users to reduce belly fat and mitigate the risk of metabolic diseases. Through these innovative approaches, Olive Healthcare aims to enhance patient care and improve health outcomes.

Cellestia

Series B in 2019
Cellestia Biotech AG is a clinical-stage biopharmaceutical company specializing in the development of innovative therapies for cancer and immunological disorders. Founded in 2014 as a spin-off from the École Polytechnique Fédérale de Lausanne, the company is headquartered in Basel, Switzerland, with an additional location in Lausanne. Cellestia focuses on its lead compound, CB-103, which is a novel oral pan-NOTCH inhibitor targeting NOTCH-dependent leukemia, lymphoma, and solid tumors. The drug has successfully advanced to Phase 2 clinical trials for patients with multi-drug resistant cancers. In addition to CB-103, Cellestia is developing a pipeline of novel transcription factor inhibitors and NOTCH-specific biomarkers to enhance patient selection and treatment outcomes. The company's approach aims to control and modulate pathogenic gene expression through selective inhibition of transcription factors in the cell nucleus, contributing to integrated drug and personalized medicine development.

Rznomics

Series A in 2019
Rznomics is a biotechnology company founded by professor Lee Sung-wook's lab, focusing on the development of innovative gene therapy products aimed at treating liver cancer and other serious medical conditions. The company specializes in ribonucleic acid-based therapies that address significant unmet medical needs, particularly in the areas of cancer, degenerative neurological disorders, and hereditary diseases. By creating new biopharmaceuticals, Rznomics aims to provide medical practitioners with effective treatment options for challenging health issues, including various types of cancer and Alzheimer’s disease. The company has garnered recognition for its technological excellence, having been selected for the TIPS program, which highlights its commitment to advancing medical science.

Vedanta Biosciences

Series C in 2019
Vedanta Biosciences, Inc. is a clinical-stage microbiome company based in Cambridge, Massachusetts, focused on developing therapies for immune-mediated and infectious diseases using human microbiome-derived bacteria. Established in 2010, the company utilizes microbial ecology and mucosal immunology to create innovative immunotherapies. Its platform includes a comprehensive library of bacteria sourced from the human microbiome, proprietary assays for selecting effective bacterial strains, and extensive datasets from human interventional studies. Vedanta also possesses cGMP-compliant manufacturing capabilities, allowing for the production of defined bacterial consortia in powder form. This enables the development of oral therapies aimed at treating autoimmune and inflammatory diseases, providing physicians with effective access to live bacterial drugs. Vedanta operates as a subsidiary of Pure Tech Health plc.

Maxst

Series B in 2019
Maxst Co Ltd is an augmented reality (AR) technology company that specializes in research and development to enhance physical reality through AR, artificial intelligence, and computer vision technology. The company offers a range of products, including an AR Software Development Kit (SDK), AR Collaboration tools, and AR Guide applications, all designed for security, reliability, and scalability. These products support various infrastructure, applications, devices, and hardware. Maxst has established partnerships with prominent organizations such as Hyundai, Kia, SK Telecom, LG Electronics, KT, and Naver, positioning itself as a leader in the AR market. Through its innovative solutions, Maxst aims to empower developers and organizations by providing immediate visual tools to improve decision-making capabilities.

Sharetreats

Series A in 2019
Sharetreats Innovation is a company based in Makati, Philippines, that has developed a platform enabling consumers to send and receive vouchers redeemable at select branches. After a payment is completed, treat codes are delivered via SMS, facilitating a straightforward gifting process. Additionally, Sharetreats promotes a cultural movement encouraging social interaction through casual gifts, offering a variety of stickers and greetings suitable for various occasions. This combination of digital vouchers and personalized greetings enhances the gifting experience for users.

Vedanta Biosciences

Series C in 2019
Vedanta Biosciences, Inc. is a clinical-stage microbiome company based in Cambridge, Massachusetts, focused on developing therapies for immune-mediated and infectious diseases using human microbiome-derived bacteria. Established in 2010, the company utilizes microbial ecology and mucosal immunology to create innovative immunotherapies. Its platform includes a comprehensive library of bacteria sourced from the human microbiome, proprietary assays for selecting effective bacterial strains, and extensive datasets from human interventional studies. Vedanta also possesses cGMP-compliant manufacturing capabilities, allowing for the production of defined bacterial consortia in powder form. This enables the development of oral therapies aimed at treating autoimmune and inflammatory diseases, providing physicians with effective access to live bacterial drugs. Vedanta operates as a subsidiary of Pure Tech Health plc.

Z-emotion

Venture Round in 2019
Z-emotion is a technology company specializing in 3D garment simulation, aimed at facilitating the digital transformation of the fashion industry. Headquartered in South Korea, with additional offices in Hong Kong and the USA, the company offers a primary product called z-weave, a 3D CAD software that allows apparel professionals to visualize their fashion concepts. Z-emotion's platform is equipped with features such as predictive analytics, a virtual showroom, custom animation, and auto stitching, which enable users to make informed decisions in garment design. The company has garnered investment support from notable strategic partners, including LG Electronics, NAVER, HTC, and Shima Seiki, further solidifying its presence in the market.

Bagelcode

Series C in 2018
Bagelcode, Inc. is a mobile gaming company based in Seoul, South Korea, founded in 2012. It specializes in developing mobile social casino games, allowing users to engage in popular casino experiences such as slots and poker on web and mobile platforms. The company has a diverse workforce of over 170 members from various countries, including the United States, Canada, and Israel, fostering a global talent pool to enhance its gaming offerings. With a user base exceeding 45 million worldwide, Bagelcode has experienced significant growth, reportedly expanding at an average rate of over 250% in recent years. The company is committed to continuous innovation and seeks to position itself as a leader in the global gaming industry by attracting top talent and enhancing user experiences.

Riiid

Series B in 2018
Riiid is a global innovator in AI-powered education solutions, specializing in adaptive assessment platforms that personalize learning experiences for students worldwide. Launched in 2017 with Santa TOEIC, its flagship product has reached over one million users in Korea alone, demonstrating proven efficacy. Expanding globally, Riiid operates Santa TOEIC in Japan and offers Santa SAT in Vietnam. Its scalable AI technology provides each student with a personalized tutor, enhancing learning outcomes while reducing costs compared to traditional methods. By democratizing educational opportunities, Riiid is rapidly transforming the learning landscape.

Infit & Company

Series A in 2018
Infit & Company Inc. is a manufacturer of medical diagnostic devices and wellness devices that targeting global healthcare industry.

Genecast

Series A in 2018
GeneCast specializes in cancer screening, monitoring, and precision care through innovative diagnostic technology. The company's method focuses on amplifying only mutated genes while preserving normal genes, enabling the detection and diagnosis of early-stage cancer. Utilizing a liquid biopsy approach, GeneCast analyzes mutant tumor DNA found in the blood, facilitating timely and accurate treatment options for cancer patients. This technology aims to enhance the precision of cancer care and improve patient outcomes.

Olive Healthcare

Series A in 2018
Olive Healthcare is a digital healthcare company specializing in medical diagnostic devices with a focus on abdominal fat scanning and breast cancer diagnosis. Utilizing non-radiative and non-invasive near infrared (NIR) technology, along with artificial intelligence algorithms and big data processing, Olive Healthcare offers customized medical services. Their devices are designed to measure abdominal fat status and provide tailored exercise and diet guidance, helping users to reduce belly fat and mitigate the risk of metabolic diseases. Through these innovative approaches, Olive Healthcare aims to enhance patient care and improve health outcomes.

J2H Biotech

Series B in 2018
J2H Biotech is a bio-venture company dedicated to the development of small-molecule drugs aimed at treating rare and challenging diseases. The company focuses on enhancing the oral absorption rates of its synthetic drugs and employs innovative patent-linked systems to facilitate the availability of generic medications for conditions such as intractable rare diseases, infectious diseases, and liver diseases. By advancing these therapeutic alternatives, J2H Biotech seeks to improve patient outcomes and expand treatment options for healthcare providers.

Bionetix Therapeutics

Venture Round in 2017
Bionetix Therapeutics is a developer of anticancer drugs designed for cancer treatment. The company's drugs include medicines for ophthalmic disease and glaucoma treatment, enabling patients to get early treatment for eye diseases, cancer and other diseases with unmet needs.

PinotBio

Series A in 2017
PinotBio, Inc., based in Suwon, South Korea, is a biotechnology company focused on researching and developing small molecule drugs in the fields of ophthalmology and oncology. The company is engaged in pre-clinical trials for NTX-101, a treatment designed for glaucoma, as well as other technologies targeting anticancer therapies through epigenetics. PinotBio aims to create innovative treatments that assist in managing refractory and relapsed cancers, enhancing the ability of healthcare providers to treat patients with life-threatening conditions. Founded in 2017, the company is dedicated to addressing unmet medical needs in these critical areas.

Moai Games

Series A in 2016
Moai Games is a gaming company that offers video and PC games.

MOAIGAMES

Series B in 2016
MOAIGAMES is a gaming platform that offers role-playing mobile and video games.

Yanolja

Series B in 2016
Yanolja is a leisure platform headquartered in Seoul, South Korea, that provides a comprehensive range of online accommodation and travel services. Founded in 2005, the company connects various aspects of travel, including lodging, leisure activities, and transportation, allowing users to book diverse hotel options globally. Yanolja leverages advanced technologies such as artificial intelligence, blockchain, and IoT to enhance its offerings. In addition to consumer services, the company provides cloud-based software solutions for hotels, residences, and leisure facilities, streamlining operations and improving efficiency across the travel industry.

Still8

Series B in 2016
In the early days of E-Sports, unrivaled skills and overflowing enthusiasm towards games were the only two requisites to become a professional gamer. Nowadays with the rise of global E-Sports fandoms, performance became only one of many requisites of a pro-gamer. Fans are connected to pro-gamers everywhere through various channels such as SNS and live & video platforms. In order to satisfy their needs and be loved by them, a professional gamer needs more than just playing games. E-Sportainment is the compound word of E-Sports and Entertainment. It’s the most explicit and mission-oriented word to describe what STILL8 does. Combining entertainment factors with E-Sports, we help current pro-gamers to boost their talents and retired pro-gamers to sustain their career. Playing games is one part, amusing fans with various entertainments is another. As so, STILL8 ultimately pursues the E-Sports of the gamer, by the gamer, and for the gamer.

MyMusicTaste

Series A in 2016
MyMusicTaste is a crowdsourcing platform dedicated to organizing live music events, specifically concerts and music festivals. It connects fans, artists, and promoters, allowing fans to request performances from their favorite artists in their local areas. By leveraging data-driven insights, MyMusicTaste empowers artists and concert promoters to effectively plan and execute successful events based on fan demand. This innovative approach facilitates a more interactive concert experience and enables a new model for organizing live events, making it easier for fans to influence the music landscape and connect with the artists they love.

Still8

Series A in 2015
In the early days of E-Sports, unrivaled skills and overflowing enthusiasm towards games were the only two requisites to become a professional gamer. Nowadays with the rise of global E-Sports fandoms, performance became only one of many requisites of a pro-gamer. Fans are connected to pro-gamers everywhere through various channels such as SNS and live & video platforms. In order to satisfy their needs and be loved by them, a professional gamer needs more than just playing games. E-Sportainment is the compound word of E-Sports and Entertainment. It’s the most explicit and mission-oriented word to describe what STILL8 does. Combining entertainment factors with E-Sports, we help current pro-gamers to boost their talents and retired pro-gamers to sustain their career. Playing games is one part, amusing fans with various entertainments is another. As so, STILL8 ultimately pursues the E-Sports of the gamer, by the gamer, and for the gamer.

Likely

Series A in 2015
Likely is an online store for women's fashion.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.